ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, D. R.
Right arrow Articles by Murray, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, D. R.
Right arrow Articles by Murray, G. F.

The Annals of Thoracic Surgery, Vol 57, 815-818, Copyright © 1994 by The Society of Thoracic Surgeons


ARTICLES

Safe use of heparin-coated bypass circuits incorporating a pump- oxygenator

DR Jones, RC Hill, A Vasilakis, MJ Hollingsed, GM Graeber, RA Gustafson, JL Cruzzavala and GF Murray
Department of Surgery, West Virginia University, Morgantown.

Durable, covalently bonded, heparin-coated cardiopulmonary bypass (CPB) circuits with oxygenators have been developed. Proposed advantages of heparin-coated CPB circuits include improved biocompatibility and thromboresistance. The purpose of this study was to evaluate our experience with heparin-coated CPB circuits in 20 patients. Heparin was given to maintain an activated clotting time equal to or greater than 200 seconds, while flow rates were kept equal to or greater than 2 L/min. Indications for use of this circuit included recent stroke, posttraumatic injuries, recent gastrointestinal bleeding, protamine allergies, combined cardiac and noncardiac procedures, and ventricular assist. Mean heparin dosage was 0.50 +/- 0.18 mg/kg and protamine dosage was 57.14 +/- 39.36 mg. Postoperative blood loss and transfusion requirements were minimal. Postoperative complement levels of C3a and C5a were normal, suggesting excellent biocompatibility. There were no deaths or perioperative complications. Heparin-coated CPB circuits using a pump oxygenator can be used safely with low-dose heparin administration in select patients requiring CPB.


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
K. V. Arom and F. L. Grover
Adult cardiac surgery during the first 50 years of the Southern Thoracic Surgical Association
Ann. Thorac. Surg., November 1, 2003; 76(90050): S17 - 46.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. C. Hill, S. Bannan, and P. G. Martin
Low heparinization and heparin-bonded circuits.
Ann. Thorac. Surg., October 1, 1997; 64(4): 1221 - 1222.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
C. Baufreton, P. G. M. Jansen, P. Le Besnerais, H. Velthuis, C. M. Thijs, C. R. H. Wildevuur, and D. Y. Loisance
Heparin Coating With Aprotinin Reduces Blood Activation During Coronary Artery Operations
Ann. Thorac. Surg., January 1, 1997; 63(1): 50 - 56.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. K. Ganjoo, M. G. Harloff, and W. D. Johnson
CARDIOPULMONARY BYPASS FOR HEPARIN-INDUCED THROMBOCYTOPENIA: MANAGEMENT WITH A HEPARIN-BONDED CIRCUIT AND ENOXAPARIN
J. Thorac. Cardiovasc. Surg., November 1, 1996; 112(5): 1390 - 1392.
[Full Text]


Home page
PerfusionHome page
S. Daniel
Review on the multifactorial aspects of bioincompatibility in CPB
Perfusion, May 1, 1996; 11(3): 246 - 255.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio
THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION
J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
E. Ovrum, E. A. Holen, G. Tangen, F. Brosstad, M. Abdelnoor, M.-A. L. Ringdal, R. Oystese, and R. Istad
Completely Heparinized Cardiopulmonary Bypass and Reduced Systemic Heparin: Clinical and Hemostatic Effects
Ann. Thorac. Surg., August 1, 1995; 60(2): 365 - 371.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
F. L. Caes, Y. V. Van Belleghem, L. H. Missault, K. E. Coenye, and G. J. Van Nooten
Surgical Treatment of Impending Paradoxical Embolism Through Patent Foramen Ovale
Ann. Thorac. Surg., June 1, 1995; 59(6): 1559 - 1561.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1994 by The Society of Thoracic Surgeons.